The NNRTI efavirenz has long been one of the most frequently employed antiretroviral drugs
in the multidrug regimens used to treat HIV infection, in accordance with its well …

Efavirenz (Sustiva®) is a first-generation non-nucleoside reverse transcriptase inhibitor
(NNRTI) used to treat human immunodeficiency virus (HIV) type 1 infection or to prevent the …

Importance of the field: The use of the first generation non-nucleoside reverse transcriptase
inhibitor efavirenz (EFV) as a component of first-line antiretroviral therapy has been …

Efavirenz primary and secondary metabolism was investigated in vitro and in vivo. In human
liver microsome (HLM) samples, 7-and 8-hydroxyefavirenz accounted for 22.5 and 77.5% of …

Objective: UDP-glucuronosyltransferase (UGT) 2B7 was recently identified as the main
enzyme mediating efavirenz N-glucuronidation. In this study, we determined whether …

Abstract Objectives Cytochrome P450 2B6 (CYP2B6) is responsible for the metabolic
clearance of efavirenz and single nucleotide polymorphisms (SNPs) in the CYP2B6 gene …

The human CYP2A gene subfamily consists of three members, CYP2A6, CYP2A7, and
CYP2A13. The CYP2A6 gene is highly polymorphic with approximately 40 annotated allelic …

Daily efavirenz 400 mg (EFV400) was virologically noninferior to 600 mg (EFV600) at 48
weeks in treatment‐naïve patients. We evaluated EFV400 and EFV600 pharmacokinetics …

Autophagy, a lysosomal catabolic pathway for long‐lived proteins and damaged organelles,
is crucial for cell homeostasis, and survival under stressful conditions. During starvation …

Hepatotoxicity is a very common side effect associated with the pharmacological treatment
of human immunodeficiency virus (HIV) infection and its pathogenesis is poorly understood …